This Biotech Company Announces Promising Leukemia Treatment Results

Shattuck Labs Announces Promising Initial Topline Data from Phase 1 A/B Dose Expansion Clinical Trial of SL-172154

Shattuck Labs, a pioneering biotech company, has recently announced the release of initial topline data from its ongoing Phase 1A/B clinical trial of SL-172154. The drug is being tested in patients diagnosed with Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML). The results have shown promise,…